NDSN · Q2 2026 Earnings
BullishNordson Corporation
Reported May 20, 2026
30-second summary
30-second take: Nordson printed Q2 revenue of $741M (+8.5% YoY, top of the prior $710–740M guide) and non-GAAP EPS of $2.86, with all three segments growing organically and backlog building to +18% YoY — a step-function jump from Q1's +4%. Management raised FY2026 revenue guidance to $2.93–3.01B (midpoint +$50M vs prior $2.86–2.98B) and FY2026 EPS to $11.30–11.80 (midpoint +$0.25), the second consecutive raise and a clean answer to last quarter's "will they raise twice" watch item. The "trough behind us" framing that took three quarters to validate has now become "increasing momentum" with explicit M&A firepower — this is the most forward-leaning Nordson has sounded in the file.
Headline numbers
EPS
Q2 FY2026
$2.86
Revenue
Q2 FY2026
$0.74B
+8.5% YoY
Gross margin
Q2 FY2026
54.5%
Operating margin
Q2 FY2026
26.6%
Key financials
Q2 FY2026| Metric | Q2 FY2026 | Q2 FY2025 | YoY | Q1 FY2026 | QoQ |
|---|---|---|---|---|---|
| Revenue | $0.74B | $0.68B | +8.5% | $0.67B | +10.8% |
| EPS | $2.86 | $2.42 | +18.2% | $2.37 | +20.7% |
| Gross margin | 54.5% | 54.7% | -20bps | 54.7% | -20bps |
| Operating margin | 26.6% | 24.7% | +190bps | 24.8% | +180bps |
Guidance
Company raised full-year FY2026 revenue and EPS guidance driven by broad-based order momentum and 18% YoY backlog growth, signaling confidence in sustained end-market strength.
Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.
Actuals vs prior guidance
| Metric | Period | Prior guide | Actual | Δ | Result |
|---|---|---|---|---|---|
| Revenue | Q2 FY2026 | $710M–$740M | $741M | +$1M above guide | Beat |
| Adjusted EPS | Q2 FY2026 | $2.70–$2.90 | $2.86 | in-line with high end of guide | Beat |
New guidance
| Metric | Period | Guide | YoY |
|---|---|---|---|
| Adjusted Tax Rate | FY2026 | 18%–19% | — |
| Revenue | Q3 FY2026 | $760M–$790M | +2.7% to +6.8% YoY |
| Adjusted EPS | Q3 FY2026 | $2.95–$3.15 | — |
| Backlog Growth (YoY organic) | Q3 FY2026 | +18% YoY | — |
Changes to prior guidance
| Metric | Period | Prior guide | New guide | Δ | Result |
|---|---|---|---|---|---|
| Revenue | FY2026 | $2,860M–$2,980M | $2,930M–$3,010M | +$50M–$30M at low/high end | Raised |
| Adjusted EPS | FY2026 | $11.00–$11.60 | $11.30–$11.80 | +$0.30–$0.20 at low/high end | Raised |
Segment KPIs
Q2 FY2026| Segment | Q2 FY2026 | Q2 FY2025 | YoY |
|---|---|---|---|
| Industrial Precision Solutions | $0.35B | $0.319B | +9.7% |
| Medical and Fluid Solutions | $0.213B | $0.203B | +4.9% |
| Advanced Technology Solutions | $0.178B | $0.161B | +10.6% |
Other KPIs
Q2 FY2026| Segment | Q2 FY2026 | Q2 FY2025 | YoY |
|---|---|---|---|
| Americas | $0.308B | $0.292B | +5.5% |
| Europe | $0.194B | $0.172B | +12.8% |
| Asia Pacific | $0.238B | $0.218B | +9.2% |
| EBITDA | $235.2M | $217 million | — |
| EBITDA margin | 31.7% | — | — |
| Backlog YoY growth | 18% | — | — |
| Organic sales growth | 6.6% | — | — |
| IPS EBITDA margin | 35.3% | — | — |
| Medical and Fluid Solutions EBITDA margin | 37.1% | — | — |
| Advanced Technology Solutions EBITDA margin | 27.2% | — | — |
Management tone
Narrative arc: Q3 FY2025 multi-segment trough call → Q4 FY2025 "headwinds behind us" optimism → Q1 FY2026 numbers validate the optimism → Q2 FY2026 momentum accelerates with M&A firepower deployed.
Three quarters ago management was hedging the trough call with "we believe" verbs while IPS printed -1.5% and ATS -3.6%. Two quarters ago they declared "key market headwinds behind us" with the segments still mixed. Last quarter the organic numbers caught up to the rhetoric. This quarter the rhetoric escalated again: "Based on the continuing momentum of our end markets as evidenced by our backlog and order entry, the Company is increasing its full year guidance." The verbal escalation is now backed by backlog +18% YoY — a four-fold step-up from Q1's +4%. This is the cleanest demand signal in the file, and it's why the second raise lands as confirmation rather than overreach.
The medical narrative completed its arc from "destocking severity reducing" (Q2 FY2025) through "destocking fully behind us" (Q4 FY2025) to this quarter's framing of a near-term regulatory product changeover as "an opportunity as the year progresses." Management quote: "After a modest first quarter, medical end markets are steadily returning to normalized growth." The Q1 "weather distortion" framing has now resolved into a structural normalization story, and the Somerville Q&A confirmed the 6-8% normalized growth target is intact. The interventional headwind that compressed MFS EBITDA margin to 37.1% (from Q4 FY2025's 39.8%) is being framed not as a margin reset but as a temporary operational inefficiency from regulatory-required material changes.
Capital allocation language has fully shifted from deleveraging to deployment. Three quarters ago management was paying down debt from the Atrion deal. Last quarter buybacks emerged as the "actionable" lever. This quarter the line is: "Our leverage ratio of 1.9 times continues to improve from last year and is now actually below the low end of our long-term target range...we are active in the M&A market with a robust pipeline." The Buscaglia exchange quantified $900M in remaining acquisition capacity. The four-consecutive-quarter >100% FCF conversion is being explicitly framed as strategic flexibility, not a cyclical artifact — "Our free cash flow conversion over 100% of net income continues to be a strength."
The portfolio repositioning language is new and worth flagging. Management said: "More than 50% of our portfolio is now in growth and markets, including semiconductor, electronics, and medical, with remaining exposures in more stable GDP plus and markets." This is the first time in the file the company has carved its portfolio explicitly into "growth markets" versus "GDP-plus" — a deliberate reframing toward secular exposure that supports the multiple. The Hammond exchange's confirmation that IPS is now in "margin maintenance, not margin expansion" mode pairs with this: the growth mix is doing the multiple work, not segment-level margin uplift.
The one hedge that persists is the explicit macro-sensitivity disclaimer. Management is rhetorically preserving downside optionality by stating exactly what would have to break for the low end to be reached: "a meaningful slowdown in order activity driven by macro conditions." Read this as confident-enough-to-raise but disciplined-enough-not-to-promise. FX, which was a contributor in H1, is going neutral in H2 — that disclosure means the H2 implied organic growth has to do more work to hit the raised range.
Recurring themes management leaned on this quarter:
Risks management surfaced:
Q&A highlights
Matt Somerville · DA Davidson
Is medical segment growth sustainably on track to deliver historical 6-8% growth rates? Can you detail the interventional product headwind from the material regulatory change?
Medical is on track to return to normalized 6-8% growth. The 8% Q2 result reflects strength in fluid dispense and engineered products. The interventional headwind is a short-term, near-term regulatory-required material changeover causing operational inefficiencies, with clear line of sight to resolution and positioned as an opportunity later in the year. Strong order entry and backlog support confidence in normalized growth return.
Jeff Hammond · KeyBank Capital Markets, Inc.
Can you explain industrial (IPS) margin compression despite decent growth? What's driving price-cost and mix dynamics and how will this play out in H2?
IPS achieved strong 4% organic growth with best-in-class margins. Margins are being pressured by a broad inflationary environment including tariffs and component/resin costs. Management is managing through selective pricing and offsetting cost actions but acknowledges lower incrementals. The focus is on maximizing growth while maintaining margin performance rather than expanding margins in this inflationary environment.
Mike Halloran · Baird
Are you assuming sequential normalcy from current trend to guidance? Are backlog conversion timelines normal or are customers building backlog further out for capacity purposes, particularly in ATS?
No fundamental change in backlog conversion timelines. Majority of backlog converts within six months, some within quarter; minority bleeds into 2027. Management has high visibility to Q3 (60% consumables with quick turnover). Being prudent on Q4 due to macro uncertainties (raw material shortages, customer pullback risks) but not seeing any of these risks materialize in current demand patterns.
Walter Liptak · Seaport Research
Can you quantify ATS order strength (single vs. double digits)? Why is there a lag from electronics dispense to T&I growth if both are strong?
ATS backlog up 18% with particular strength in segment. Order strength can be inferred as double digits or in line with/better than 18% overall backlog growth. No lag between dispense and T&I—dispense is currently stronger simply because there are more dispense units per line than T&I units. Demand levels are similar; it's a product mix dynamic. ATS is now much broader than historically with multiple technology types.
Andrew Buscaglia · BNP Paribas
In IPS, are customers signaling confidence in CapEx decisions for bigger systems, or is that already underway in backlog? Also, what's the M&A pipeline and capacity for deals given $900M remaining capacity?
Improved order entry in both systems and parts signals broader recovery confidence. IPS achieving 4% organic growth at high end with strong backlog building. No fundamental change in systems vs. parts mix (~60-40, stable Q2). M&A pipeline is robust and active; company remains disciplined on strategic and financial return criteria. Focus areas: medical growth, test inspection, technology bolt-ons, and industrial/ATS capabilities.
Answers to last quarter's watch list
What to watch into next quarter
Q3 ATS organic growth against the Q3 FY2025 base of -3.6% YoY — with backlog +18% and order strength running "double digits or better," anything below +8% organic would suggest the FY raise embeds more H2 cushion than needed and a third raise becomes likely; anything below +3% would force a reread of the backlog conversion thesis
IPS EBITDA margin holding at or above 35% while inflation (tariffs, components, resins) flows through — the Hammond exchange confirmed management is in "margin maintenance" mode, so any slip below 34% would signal pricing isn't keeping pace with cost inflation
The interventional medical product changeover "becoming an opportunity as the year progresses" — Q3 MFS EBITDA margin needs to walk back from 37.1% toward the 38-40% historical range to validate management's framing that the headwind is temporary
Whether the third consecutive FY guidance raise materializes on the Q3 print — back-to-back-to-back raises with the low end of each pulled up more than the high would confirm management is genuinely conservative; a Q3 beat followed by reaffirmed (not raised) guide would signal H2 macro caution
Backlog YoY trajectory — holding at +15% or better in Q3 would confirm the demand signal is structural; a sharp step-down below +10% would compress the FY cushion and invalidate the broad-based order momentum thesis
M&A pipeline conversion — Capstan AG was a small bolt-on; the larger strategic question is whether the $900M acquisition capacity gets deployed into a medical, test/inspection, or technology bolt-on of meaningful scale, or whether another quarter passes with qualitative pipeline language and no scaled execution
FX rolling from H1 tailwind to H2 neutral — implied H2 organic growth has to do more work to hit the raised FY range; watch whether Q3 organic prints accelerate from Q2's +6.6% or whether the FX comp drag flattens reported growth
Sources
- Nordson Corporation Q2 FY2026 press release — https://www.sec.gov/Archives/edgar/data/72331/000007233126000022/ndsn-q220268kxex991.htm
- Nordson Corporation Q2 FY2026 earnings call transcript
Get the next brief, free.
We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.
This is not investment advice.